Two widely advertised Alzheimer’s drugs It has been shown to allow patients to stay in their homes, live independently, for a long time.
However, these drugs, although effective, are not without their risks and side effects.
This is according to a recent study published last week in Alzheimer’s Association.
Red meat could increase the risk of dementia, researchers claim, but some doctors have questions
Researchers at the Faculty of Medicine, University of Washington in St. Louis analyzed how long 282 Alzheimer’s patients were able to continue to live independently after two specific treatments: Lecanese (Leqembi) and Donnemab (Kisunla).
Two widely advertised Alzheimer’s drugs have been shown to allow patients to stay in their homes, live independently, for a long time. (East)
Both drugs approved FDA are designed to remove amyloid beta plaques from the brain of people with an early stage Alzheimer’s diseasePotential slowing down the rate of cognitive fall.
Patients who took the lecaneneb extended their time at home for an additional 10 months, while Donneneb allowed them to live for another eight months, according to a publication in Wash.
Remembrance loss is not always alzheimer’s: experts warn of the usual but little known dementia
On average, a patient with mild symptoms could expect to live independently for another 29 months without treatment, 39 months with Lecanebeb and 37 months with Donamab, the statement said.
These results were based on patients who began treatment with “very mild symptoms”.
“If you mean the costs and consequences that you cannot live on your own, it could be significant for many older adults.”
“Using clinical trial data, we have calculated that, for the average patient with very mild symptoms due to the dementia of Alzheimer’s disease, he is treatment with any with any Lecaneseb or donnemab It would be expected that an independent life would extend about a year, “for Fox News Digital, Senior author Sarah Hartz, MD.
“If you think of the costs and consequences that you cannot live on your own, it might be significant for many older adults. “
On average, a patient with mild symptoms could expect to live independently for another 29 months without treatment, 39 months with lecanebeb and 37 months with Donamab. (East)
This study gives patients and their families a way to translate clinical trials into significant outcomes, Hartz states.
“For example, if the patient is considering taking Lecanese or Donamab to treat his ad, part of the discussion with his doctor may be how long they would expect to be able to worry about his bodies independently.”
3 characters that your aging loved person may be ready for a supported life
The purpose of the study is not advocating for or against these drugs, Hartz noted in a press release. “Purpose … is to put the impact of these drugs in context in ways that can help people make decisions that are best for themselves and their Family members. “
Christopher Weber, a doctor of science, a senior director of global scientific initiatives in the Alzheimer Association, was not involved in the studio, but shared his contribution to Fox News Digital.
Anyone who thinks about these treatments should have a “deep conversation” with a doctor about potential benefits and dare them against “significant risks” involved, according to the doctor. (East)
“This study suggests that these drugs have a clinically significant impact on the wounds of Alzheimer’s patients and their families, providing more time in the early stages of the disease, when patients have greater functional independence,” he said.
Studies findings highlight the importance of early treatment to maximize Potential benefitsAccording to Weber, because the beginning of a more advanced point resulted in fewer months of independence.
Click here to get the Fox News app
“The progress we see in Alzheimer’s treatments is based on decades of research and emphasizes the importance of continuous innovation and investment in this field to better understand the fundamental biology and pathway of the disease, discover it earlier, and effectively treated and effectively treated and treated and effectively treat it and effectively and effectively They treated and effectively treated and effectively treated and effectively treated to prevent it, “he added.
Potential risks and restrictions
The biggest limit of the study, according to Hartz, is that the participants were very dedicated to Alzheimer’s research and were usually highly educated.
“We do not know how our discoveries are translated into the rest of the population,” she admitted.
Both drugs approved by the FDA are designed to remove amyloid beta plaques from the brain of people with Alzheimer’s early stage, potentially slowing down the cognitive fall rate. (AP Photo/Evan Vucci, File)
Dr. Chris Vercammen, Committee Certificate internal medicine A doctor who specializes in geriatrics and palliative care, he stressed that although two drugs can expand periods of independence for people with Alzheimer’s, “Lecammonab and Donamab do not stop or turn Alzheimer’s disease.”
“It is also important to understand that these new drugs are useful only for individuals in the early stages of the disease,” said the doctor, who is also the medical director at Remo Health, California, for Fox News Digital. (Vercammen was not involved in a new study.)
Click here to sign up for our Health Bulletin
Everyone who thinks about these treatments should have a “deep conversation” with a doctor about potential benefits and dare them against “significant risks,” Verscammen states.
“These risks include the possibility of serious side effects, such as Brain swelling and bleedingAs well as significant financial costs associated with treatment, even if you have insurance, “he warned.
“These new drugs are only useful for individuals in the early stages of the disease.”
For people who can benefit from these treatments, Hartz recommends talking to their doctors and examining potential risks and benefits.
For more health articles visit www.foxnews.com/health/health
“This information could help contextualize how medicines can benefit them in terms of independence,” she added.
Fox News Digital addressed the manufacturers of Leqembija and Kisunle to ask for a comment.
